Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Notes Payables: 2012-2024

Historic Notes Payables for Aytu Biopharma (AYTU) over the last 2 years, with Dec 2024 value amounting to $4.0 million.

  • Aytu Biopharma's Notes Payables rose 291.03% to $4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.0 million, marking a year-over-year increase of 291.03%. This contributed to the annual value of $2.4 million for FY2024, which is 53.23% up from last year.
  • According to the latest figures from Q4 2024, Aytu Biopharma's Notes Payables is $4.0 million, which was down 6.04% from $4.3 million recorded in Q3 2024.
  • Aytu Biopharma's Notes Payables' 5-year high stood at $10.4 million during Q1 2023, with a 5-year trough of $41,318 in Q4 2020.
  • For the 3-year period, Aytu Biopharma's Notes Payables averaged around $3.8 million, with its median value being $3.1 million (2022).
  • Per our database at Business Quant, Aytu Biopharma's Notes Payables plummeted by 86.19% in 2023 and then surged by 291.03% in 2024.
  • Aytu Biopharma's Notes Payables (Quarterly) stood at $41,318 in 2020, then reached $7.4 million in 2022, then crashed by 86.19% to $1.0 million in 2023, then spiked by 291.03% to $4.0 million in 2024.
  • Its Notes Payables was $4.0 million in Q4 2024, compared to $4.3 million in Q3 2024 and $2.4 million in Q2 2024.